Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) ...

Myriad Genetics generated approximately $10 million and $40 million of GeneSight revenue from UNH's commercial population in ...

Myriad Genetics (MYGN) reported $213.3 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 11.2%. EPS of $0.06 for the same period compares to -$0.03 a ...

Myriad Genetics (MYGN) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.03 per share a year ago. These figures ...

In a report released yesterday, Daniel Brennan from TD Cowen maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Thursday reported a loss of $22.1 million in its third quarter. On a per-share basis, the Salt Lake City-based company said ...

Ahead of the Bengals-Giants game on Sunday, Oct. 13, Jill joined the program to discuss her history with breast cancer and urge viewers to consider genetic testing if they're high risk — a step ...